陇神戎发(300534) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was CNY 296,323,324.22, representing a 153.50% increase compared to CNY 116,891,100.59 in the same period last year[5] - Net profit attributable to shareholders reached CNY 20,005,326.86, a significant increase of 561.90% from CNY 3,022,415.06 year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 19,148,944.98, marking an increase of 8,701.24% compared to CNY 217,571.08 in the previous year[5] - Basic and diluted earnings per share were both CNY 0.0659, reflecting a 559.00% increase from CNY 0.0100 in the same quarter last year[5] - Operating profit for Q1 2023 was ¥35,336,717.29, compared to ¥4,492,429.34 in Q1 2022, indicating a year-over-year increase of about 684.5%[36] - Net profit for Q1 2023 was ¥29,294,351.56, up from ¥4,188,967.84 in Q1 2022, reflecting an increase of approximately 598.5%[37] Assets and Liabilities - The company's total assets at the end of the reporting period were CNY 1,272,480,801.75, a decrease of 2.22% from CNY 1,301,365,496.46 at the end of the previous year[5] - Total liabilities were reported at CNY 421,084,832.97, with current liabilities constituting CNY 394,191,865.02[12] - Total liabilities as of Q1 2023 amounted to ¥619,544,386.70, an increase from ¥421,084,832.97 in the previous year, representing a rise of about 47.0%[36] - The company reported a total current assets of CNY 673,721,026.00 as of March 31, 2023, down from CNY 711,399,782.20 at the beginning of the year, a decrease of approximately 5.3%[33] Cash Flow - The company reported a net cash flow from operating activities of -CNY 30,165,723.04, a decline of 209.91% compared to CNY 27,445,744.07 in the previous year[5] - Cash inflow from operating activities was CNY 295,872,942.31, compared to CNY 168,258,035.38 in the previous year, representing an increase of approximately 76%[40] - The net cash outflow from operating activities was CNY -30,165,723.04, a decline from a net inflow of CNY 27,445,744.07 in the same period last year[40] - The ending balance of cash and cash equivalents was CNY 276,917,982.46, down from CNY 369,244,036.02 at the beginning of the period[41] Investments and Acquisitions - The company completed the acquisition of a 70% stake in Gansu Puan Pharmaceutical Co., Ltd., which was reflected in the financial adjustments for the quarter[8] - The company completed the acquisition of 70% equity in Puan Pharmaceutical, with the transfer of ownership finalized on February 8, 2023[28] - The company signed a contract for the production of "Xuanfei Zhike Decoction" with a minimum monthly production of 100,000 boxes, with production costs set at CNY 10.35 per box for the first two months, reducing to CNY 10.00 thereafter[28] Research and Development - Research and development expenses for the quarter totaled CNY 4,656,354.38, indicating ongoing investment in innovation[15] - Research and development expenses for Q1 2023 were ¥5,717,764.87, compared to ¥4,656,354.38 in Q1 2022, indicating an increase of approximately 22.8%[36] Shareholder Information - The number of ordinary shareholders at the end of the period was 34,255[24] - The largest shareholder, Gansu Pharmaceutical Investment Group, holds 29.93% of the shares[24] Management Changes - The company appointed Qian Shuangxi as the new General Manager on March 10, 2023, following the resignation of the previous General Manager[30] Other Financial Metrics - The company reported a gross profit margin of approximately 36.5% based on total operating revenue and total operating costs[14] - Total operating costs rose by 105.71% compared to the beginning of the period, primarily due to the increase in operating revenue[21] - The company plans to continue expanding its market presence and investing in new product development to sustain growth in the upcoming quarters[36]